Skip to content

A Trial of Levator Muscle Blocks Following Posterior Colporrhaphy Surgery to Reduce Post-operative Pain.

A Multicenter, Double Blinded, Randomized Controlled Trial of Levator Muscle Blocks Following Posterior Colporrhaphy Surgery to Reduce Post-operative Pain.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03067168
Enrollment
128
Registered
2017-03-01
Start date
2017-05-15
Completion date
2019-08-01
Last updated
2019-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post Operative Pain

Brief summary

To determine if levator muscle block with bupivacaine improves postoperative pain control relative to placebo controls among women undergoing prolapse surgery involving a posterior colporrhaphy. Improvement is defined as no less than a 25% lower total pain score on a ten point numerical pain scale.

Interventions

DRUGBupivacaine

5 mL of 0.5% bupivacaine will be injected into 2 locations bilaterally.

DRUGnormal saline 0.9%

5 mL of 0.9% normal saline will be injected into 2 locations bilaterally.

Sponsors

University of Kansas Medical Center
CollaboratorOTHER
The Christ Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

Subjects will not know if they received an injection of bupivacaine or placebo, i.e., normal saline after completion of surgery. The surgeon, as well as any investigator or study personnel, will be blinded to injection type.

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Any woman over the age of 18 years with a capacity to give informed consent who are undergoing vaginal prolapse surgery including a posterior colporrhaphy may be included in the study.

Exclusion criteria

* Any woman who is a non-English speaker, does not have ability to provide consent, has a cardiac arrhythmia, liver disease, myasthenia gravis, bleeding diathesis or adverse reaction / allergy to anesthetic will be excluded. Women that are also having vaginal mesh excisions at the time of prolapse repair or those that will undergo subsequent surgery in the follow up period will be excluded.

Design outcomes

Primary

MeasureTime frameDescription
Number of patients with improvement in pain, scored on a 10 point numerical pain scale.1 yearImprovement is defined as a 25% or lower total pain score on a ten point numerical pain scale compared to placebo.

Secondary

MeasureTime frameDescription
Postoperative care satisfaction scores, graded with a post-operative survey.1 yearImprovement in satisfaction is defined as an overall satisfaction score of 20% or more on the post-operative survey compared to placebo.
Measure of morphine equivalents used in patients postoperatively.1 yearA reduction in opiate use is defined as a 20% reduction in total number of morphine equivalents used between study cohorts.
Length of hospital stay measured in hours.1 yearLength, in hours, of hospital stay between study cohorts.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026